{"organizations": [], "uuid": "f75689ec5486ef77ab24abf6bfb3c407b43f5360", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ultragenyx-and-kyowa-kirin-announc/brief-ultragenyx-and-kyowa-kirin-announce-crysvita-now-launched-in-the-u-s-idUSFWN1S70Y9", "country": "US", "domain_rank": 408, "title": "BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S.", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T15:55:00.000+03:00", "replies_count": 0, "uuid": "f75689ec5486ef77ab24abf6bfb3c407b43f5360"}, "author": "", "url": "https://www.reuters.com/article/brief-ultragenyx-and-kyowa-kirin-announc/brief-ultragenyx-and-kyowa-kirin-announce-crysvita-now-launched-in-the-u-s-idUSFWN1S70Y9", "ord_in_thread": 0, "title": "BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S.", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "kyowa kirin announce crysvita", "sentiment": "none"}], "organizations": [{"name": "kyowa kirin", "sentiment": "negative"}, {"name": "ultragenyx pharmaceutical inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "u.s. reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 12:55 PM / Updated 7 minutes ago BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S. Reuters Staff 1 Min Read\nApril 30 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE CRYSVITA® (BUROSUMAB-TWZA) NOW LAUNCHED IN THE U.S. FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA (XLH) IN CHILDREN AND ADULTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-30T15:55:00.000+03:00", "crawled": "2018-04-30T16:12:44.014+03:00", "highlightTitle": ""}